318306--5/1/2006--ACCESS_PHARMACEUTICALS

related topics

{product, candidate, development}

{control, financial, internal}

{stock, price, share}

{cost, regulation, environmental}

{product, liability, claim}

{product, market, service}

{provision, law, control}

{property, intellectual, protect}

{personnel, key, retain}

{stock, price, operating}

{regulation, government, change}

We may not successfully commercialize our drug candidates. The success of our research and development activities, upon which we primarily focus, is uncertain. We may be unable to successfully develop, market, or commercialize our products or our product candidates without establishing new relationships and maintaining current relationships. We may be unable to successfully manufacture our products and our product candidates in clinical quantities or for commercial purposes without the assistance of contract manufacturers, which may be difficult for us to obtain and maintain. We are subject to extensive governmental regulation which increases our cost of doing business and may affect our ability to commercialize any new products that we may develop. The uncertainty associated with preclinical and clinical testing may affect our ability to successfully commercialize new products. We may incur substantial product liability expenses due to the use or misuse of our products for which we may be unable to obtain insurance coverage. We may incur significant liabilities if we fail to comply with stringent environmental regulations or if we did not comply with these regulations in the past. Intense competition may limit our ability to successfully develop and market commercial products. Our ability to successfully develop and commercialize our drug candidates will substantially depend upon the availability of reimbursement funds for the costs of the resulting drugs and related treatments. The market may not accept any pharmaceutical products that we successfully develop. Trends toward managed health care and downward price pressures on medical products and services may limit our ability to profitably sell any drugs that we may develop. We may not be successful in protecting our intellectual property and proprietary rights. Our business could suffer if we lose the services of, or fail to attract, key personnel. An investment in our common stock may be less attractive because it is not traded on a recognized public market. Ownership of our shares is concentrated, to some extent, in the hands of a few investors which could limit the ability of our other stockholders to influence the direction of the company. Provisions of our charter documents could discourage an acquisition of our company that would benefit our stockholders and may have the effect of entrenching, and making it difficult to remove, management. Substantial sales of our common stock could lower our stock price. Failure to achieve and maintain effective internal controls could have a material adverse effect on our business. Effective internal controls are necessary for us to provide reliable financial reports. If we cannot provide reliable financial reports, our operating results could be harmed. All internal control systems, no matter how well designed,

Full 10-K form ▸

318306--5/1/2006--ACCESS_PHARMACEUTICALS_INC